[an error occurred while processing this directive] | [an error occurred while processing this directive]
Partial stereotactic ablative boost radiotherapy in bulky non‐small cell lung cancer: a dosimetric comparison between proton and photon
Bai Yun1, Gao Xianshu1, Ma Mingwei1, Zhao Zhilei2, Liu Peilin1, Cao Xi1, Qin Shangbin1, Liu Siwei1, Gao Yan1, Ren Xueying1, Li Hongzhen1, Zhang Min1, Li Xiaomei1, Lyu Feng1, Li Xiaoying1, Qi Xin1, Chen Jiayan1, Xie Mu1
1Department of Radiation Oncology, Peking University First Hospital, Beijing 100034, China; 2Department of Radiation Oncology, Hebei Yizhou Cancer Hospital, Zhuozhou 072750, China
AbstractObjective Partial stereotactic ablative boost radiotherapy(P‐SABR)is a method to deliver SABR boost to the gross tumor boost volume(GTVb), followed by conventionally fractionated radiotherapy to the whole tumor area(GTV). GTVb is the max volume receiving SABR while ensuring the critical organ‐at‐risk(OAR)falloff to 3 GyE/f. We investigated the potential advantage of proton therapy in treating bulky non‐small cell lung cancer(the tumor length greater than 8 cm). Methods Nine patients with bulky NSCLC treated with photon P‐SABR in our institute were selected. For the treatment planning of proton therapy, the GTVb target area was gradually outwardly expanded based on the photon GTVb target area until the dose to critical OARs reached 3 GyE/f. The GTV and CTV areas remained the same as photon plan. A proton intensity‐modulated radiation treatment plan(proton‐IMPT), a photon intensity‐modulated radiation treatment plan(photon‐IMRT)and a photon volumetric modulated arc therapy(photon‐VMAT)were created for each patient, respectively. The dosimetric parameters of different treatment plans were compared. Results The volume ratio of GTVb‐photon and GTVb‐proton to GTV was(25.4±13.4)% and(69.7±30.0)%,respectively(P<0.001). In photon‐IMRT, photon‐VMAT, and proton‐IMPT plan groups, the mean dose of CTV was(76.1±4.9)Gy, (78.2±3.6)Gy, and(84.7±4.9)Gy, respectively; the ratio of tumor volume with Biologic Effective Dose(BED)≥ 90 Gy to GTV volume was(70.7±21.7)%, (76.8±22.1)%,and(97.9±4.0)%,respectively. The actual dose and BED to the tumor area of the proton‐IMPT plan group were significantly higher than those of the photon plan group(both P<0.05). Besides, the OARs dose was significantly decreased in the proton‐IMPT group, with(49.2±22.0)%, (56.8±19.0)% and(16.1±6.3)% of the whole lung V5 for photon‐IMRT, photon‐VMAT and proton‐IMPT, respectively(all P<0.001). Conclusions Larger GTV boost target volume, higher BED and reduced OARs dose can be achieved in proton plans compared with photon plans. Proton P‐SABR is expected to further improve the local control rate of bulky NSCLC with fewer adverse effects.
Bai Yun,Gao Xianshu,Ma Mingwei et al. Partial stereotactic ablative boost radiotherapy in bulky non‐small cell lung cancer: a dosimetric comparison between proton and photon[J]. Chinese Journal of Radiation Oncology, 2022, 31(8): 710-715.
Bai Yun,Gao Xianshu,Ma Mingwei et al. Partial stereotactic ablative boost radiotherapy in bulky non‐small cell lung cancer: a dosimetric comparison between proton and photon[J]. Chinese Journal of Radiation Oncology, 2022, 31(8): 710-715.
[1] Johnson CR, Thames HD, Huang DT, et al.The tumor volume and clonogen number relationship ‐ tumor‐control predictions based upon tumor volume estimates derived from computed‐tomography[J]. Int J Radiat Oncol Biol Phys, 1995,33(2): 281‐287.DOI: 10.1016/0360‐3016(95)00119‐J.
[2] Ball DL, Fisher RJ, Burmeister BH, et al.The complex relationship between lung tumor volume and survival in patients with non‐small cell lung cancer treated by definitive radiotherapy: a prospective, observational prognostic factor study of the Trans‐Tasman Radiation Oncology Group(TROG 99.05)[J]. Radiother Oncol,2013,106(3):305‐311.DOI:10.1016/j.radonc.2012.12.003.
[3] Bai Y, Gao XS, Qin SB, et al.Partial stereotactic ablative boost radiotherapy in bulky non‐small cell lung cancer: a retrospective study[J]. Onco Targets Ther, 2018,11:2571‐2579.DOI: 10.2147/OTT.S159538.
[4] Ohno T, Oshiro Y, Mizumoto M, et al.Comparison of dose‐volume histograms between proton beam and X‐ray conformal radiotherapy for locally advanced non‐small‐cell lung cancer[J]. J Radiat Res, 2015,56(1): 128‐133.DOI: 10.1093/jrr/rru082.
[5] Paganetti H.Range uncertainties in proton therapy and the role of Monte Carlo simulations[J]. Phys Med Biol, 2012,57(11): R99‐117.DOI: 10.1088/0031‐9155/57/11/R99.
[6] Li H, Zhu XR, Zhang X.Reducing dose uncertainty for spot‐scanning proton beam therapy of moving tumors by optimizing the spot delivery sequence[J]. Int J Radiat Oncol Biol Phys, 2015,93(3): 547‐556.DOI: 10.1016/j.ijrobp.2015.06.019.
[7] Marks LB, Yorke ED, Jackson A, et al.Use of normal tissue complication probability models in the clinic[J]. Int J Radiat Oncol Biol Phys,2010,76(3 Suppl):S10‐19.DOI:10.1016/j.ijrobp.2009.07.1754.
[8] Ohtakara K, Hayashi S, Hoshi H.The relation between various conformity indices and the influence of the target coverage difference in prescription isodose surface on these values in intracranial stereotactic radiosurgery[J]. Br J Radiol, 2012,85(1014): e223‐228.DOI: 10.1259/bjr/36606138.
[9] Seco J, Gu G, Marcelos T, et al.Proton arc reduces range uncertainty effects and improves conformality compared with photon volumetric modulated arc therapy in stereotactic body radiation therapy for non‐small cell lung cancer[J]. Int J Radiat Oncol Biol Phys,2013,87(1):188‐194.DOI:10.1016/j.ijrobp.2013.04.048.
[10] Chang JY, Senan S, Paul MA, et al.Stereotactic ablative radiotherapy versus lobectomy for operable stage I non‐small‐cell lung cancer: a pooled analysis of two randomised trials[J]. Lancet Oncol, 2015,16(6): 630‐637.DOI: 10.1016/S1470‐2045(15)70168‐3.
[11] Sampath S.Treatment: radiation therapy[J]. Cancer Treat Res, 2016,170:105‐118.DOI: 10.1007/978‐3‐319‐40389‐2_5.
[12] Zhao J, Yorke ED, Li L, et al.Simple factors associated with radiation‐induced lung toxicity after stereotactic body radiation therapy of the thorax: a pooled analysis of 88 studies[J]. Int J Radiat Oncol Biol Phys, 2016,95(5): 1357‐1366.DOI: 10.1016/j.ijrobp.2016.03.024.
[13] Choi JI, Simone CB.Breaking the dose ceiling: proton therapy for locally advanced non‐small cell lung cancer[J]. J Thorac Dis, 2018,10(1): 130‐134.DOI: 10.21037/jtd.2017.12.79.
[14] Zhang X, Li Y, Pan X, et al.Intensity‐modulated proton therapy reduces the dose to normal tissue compared with intensity‐modulated radiation therapy or passive scattering proton therapy and enables individualized radical radiotherapy for extensive stageⅢB non‐small‐cell lung cancer: a virtual clinical study[J]. Int J Radiat Oncol Biol Phys, 2010,77(2): 357‐366.DOI: 10.1016/j.ijrobp.2009.04.028.
[15] Xiao Y, Kry SF, Popple R, et al.Flattening filter‐free accelerators: a report from the AAPM Therapy Emerging Technology Assessment Work Group[J]. J Appl Clin Med Phys, 2015,16(3): 5219.DOI: 10.1120/jacmp.v16i3.5219.
[16] Han T, Followill D, Mikell J, et al.Dosimetric impact of Acuros XB deterministic radiation transport algorithm for heterogeneous dose calculation in lung cancer[J]. Med Phys, 2013,40(5): 051710.DOI: 10.1118/1.4802216.
2022, Vol. 31 
